GT Biopharma is trading at $6.59, down 7.18%, with the decline most consistent with biotech-sector weakness and broader risk-off pressure.
- No new company-specific announcement was identified for September 24, 2026.
- Its latest prominent catalyst was September 15 FDA clearance for GTB-5550’s multiple-myeloma trial; the financing announcement also dates to that period.
- Broader risk-off pressure is linked to rising Treasury yields and inflation concerns. Momentum after earlier clinical-development news may also be unwinding, though that is not confirmed as the direct cause.